South African Institute for Drug-Free Sport v. Asenathi Ntlabakanye

Springbok and Emirates Lions tighthead prop Asenathi Ntlabakanye returned an adverse analytical finding for Anastrozole, a hormone and metabolic modulator, in an out-of-competition sample collected on 22 May 2025. Anastrozole is classified as a Specified Substance under the South African Anti-Doping Rules, meaning it does not trigger a mandatory provisional suspension on its own. Separately, and on his own initiative, Ntlabakanye declared on a doping-control form that he was also using dehydroepiandrosterone (DHEA), an anabolic steroid classified as a Non-Specified Substance. He was formally charged with both matters on 9 September 2025.

Ntlabakanye did not deny using either substance. His defence was that both had been prescribed by an endocrinologist he consulted for a weight-management issue, and that he had separately cleared the medication with a sports doctor appointed to oversee the medical affairs of professional rugby players, before ever taking it. He maintained he had acted transparently throughout — declaring the DHEA use himself rather than having it detected by testing — and contested the charge rather than accepting a negotiated sanction.

The matter went to a full hearing before an Independent Doping Hearing Panel, held over two days in March 2026, with closing arguments from both Ntlabakanye and SAIDS delivered on 21 April 2026. The Panel had to weigh whether the violation was intentional, the athlete's degree of fault given the medical prescription and multi-step verification he described, and the appropriate sanction under a framework that treats Specified and Non-Specified substances differently by default. After three weeks of deliberation, the Panel imposed an 18-month period of ineligibility — a sanction well below the four-year term ordinarily associated with a Non-Specified Substance violation not proven to be unintentional, but still a meaningful ban given his profile and timing.

The ban runs from 13 May 2026 to 13 November 2027 — a date that, not coincidentally, falls on the day of the 2027 Rugby World Cup final in Australia, ruling Ntlabakanye out of the tournament entirely and, by some estimates, costing him conservatively around R5 million in lost earnings over the period. Of the three separate medications the endocrinologist had prescribed him, two turned out to contain the substances at issue. The Panel also disqualified his individual competitive results and personal benefits (player-of-the-match honours, personal accolades, match fees, and bonuses) from the date of sample collection onward, while expressly confirming this disqualification does not extend to any team result Ntlabakanye played a part in. Ntlabakanye, SAIDS, World Rugby, and WADA each retained 21 days from the decision to appeal to the Court of Arbitration for Sport. As of early June 2026, reporting indicated Ntlabakanye had "little appetite" to pursue an appeal as the deadline approached.

The case is a useful illustration of how a Specified/Non-Specified substance framework actually operates when an athlete volunteers information against his own interest: Ntlabakanye's self-declaration of the DHEA use is precisely the kind of fact that can support a finding of transparency and reduced fault, even though it also supplied the evidentiary basis for the more serious of the two charges against him.